|
KMID : 0939920090410010024
|
|
대한암학회지
2009 Volume.41 No. 1 p.24 ~ p.28
|
|
|
Uterine Leiomyosarcoma : 14-year Two-center Experience of 31 Cases
|
|
Kim Woo-Young
Chang Suk-Joon
Chang Ki-Hong
Yoon Jong-Hyuck
Kim Jang-Hee
Kim Byoung-Gie
Bae Duk-Soo
Ryu Hee-Sug
|
|
|
Abstract
|
|
|
Purpose:The aim of this study was to evaluate the clinicopathological characteristics of uterineleiomyosarcoma (LMS) and possible prognostic factors.
Materials and Methods:This study included 31 patients with histologically proven LMS at Samsung Medical Centerand Ajou University Hospital between 1994 and 2007. The medical records and availablehistological slides were reviewed retrospectively.
Results:The median age was 46 years (range, 32∼63). The most common symptom was vaginalbleeding (11 patients, 35.5%). There were 23 patients with stage I, one patient with stage III,seven patients with stage IV disease. The median follow up time was 29 months (range, 1∼94). The most common recurrence site was lung (5 case), followed by pelvis and upperabdomen (2 case). Nine patients died of disease with a 5-year overall survival rate of 63%.Early tumor stage and mitotic count were the prognostic factor in univariate analysis(p<0.0001 and p=0.0031, respectively), but early tumor stage only was associated withprognosis in multivariate analysis (p=0.010 vs p=0.143). Adjuvant treatment for early stagedisease did not decrease the recurrence rate (p=0.1075), but high mitotic count (15>10HPF)had a trend for disease recurrence in early stage LMS (p=0.0859).
Conclusion:Mitotic count less than 15/HPF in early stage may be related with longer progression-freeinterval, but we could not reach the conclusion that adjuvant therapy in early stage LMS beeffective.
|
|
|
KEYWORD
|
|
|
Stage, Mitotic count, Adjuvant therapy, Prognostic factor
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
    
|
|